[1] NAKAZAWA T, ANDO T, HAYASHI K, et al. Diagnostic procedures for IgG4-related sclerosing cholangitis[J]. J Hepatobiliary Pancreat Sci, 2011, 18(2):127-136.
|
[2] HEGADE VS, SHERIDAN MB, HUGGETT MT. Diagnosis and management of IgG4-related disease[J]. Frontline Gastroenterol, 2019, 10(3):275-283.
|
[3] YONG HF, DONG X, WANG WS, et al. Computed tomography and magnetic resonance imaging features of IgG4-related pancreatitis[J]. Chin J Dig Surg, 2019, 18(7):689-697.(in Chinese)雍惠芳,董雪,王文森,等.IgG4相关性胰腺炎CT和MRI检查的影像学特征[J].中华消化外科杂志,2019, 18(7):689-697.
|
[4] MORRIS-STIFF G, TELI M, JARDINE N, et al. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease[J]. Hepatobiliary Pancreat Dis Int,2009, 8(6):620-626.
|
[5] TAN L, GUAN X, ZENG T, et al. The significance of serum IgG4 and CA19-9, autoantibodies in diagnosis and differential diagnosis of IgG4-related sclerosing cholangitis[J].Scand J Gastroenterol, 2018, 53(2):206-211.
|